Dr Agarwal's Eye

Which are the latest news on Dr Agarwal's Eye?

Why is Dr Agarwals Eye Hospital Ltd falling/rising?

As of 05-Sep, Dr Agarwals Eye Hospital Ltd's stock price is at 5,392.40, showing a 1.05% increase and outperforming the Sensex over the past week and month. The stock's positive trend is supported by strong fundamentals, consistent growth, and a favorable debt-equity ratio, despite a decrease in investor participation.

As of 05-Sep, Dr Agarwals Eye Hospital Ltd's stock price is rising, currently at 5,392.40, reflecting an increase of 55.85 (1.05%). The stock has demonstrated strong performance relative to the benchmark Sensex, outperforming it by 3.20% over the past week and 6.03% over the past month, while the Sensex has declined by 0.97% and 2.44%, respectively. <BR><BR>Today's trading session saw the stock open with a gain of 2.59%, reaching an intraday high of Rs 5,475. Additionally, the stock is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a positive trend. Despite a noted decrease in investor participation, with delivery volume falling by 51.75% against the 5-day average, the stock remains liquid enough for trading.<BR><BR>The company's fundamentals support this upward movement, as it has reported consistent growth in net sales at an annual rate of 26.13% and operating profit at 38.49%. Furthermore, the company has achieved positive results for the last six consecutive quarters, with a debt-equity ratio at its lowest of 0.94 times and a significant increase in net sales for the last quarter at Rs 142.97 crore, growing by 22.28%. The stock's performance over the past year, generating a return of 19.70% alongside a profit increase of 31.9%, further reinforces its rising trend. Overall, these factors contribute to the stock's current upward movement.

Who are in the management team of Dr Agarwal's Eye?

The management team of Dr Agarwal's Eye includes Amar Agarwal (Chairman/Executive Director), Athiya Agarwal (Whole Time Director), Sanjay Anand, Adil Agarwal, Lakshmmi Subramanian, and V Balakrishnan as Independent Non-Executive Directors, bringing diverse expertise to the company's leadership.

The management team of Dr Agarwal's Eye includes the following individuals:<BR><BR>1. **Amar Agarwal** - Chairman / Executive Director<BR>2. **Athiya Agarwal** - Whole Time Director & Executive Director<BR>3. **Sanjay Anand** - Independent Non-Executive Director<BR>4. **Adil Agarwal** - Non-Executive Director<BR>5. **Lakshmmi Subramanian** - Independent Non-Executive Director<BR>6. **V Balakrishnan** - Independent Non-Executive Director<BR><BR>This team brings a diverse range of expertise to the company, contributing to its leadership and strategic direction.

What does Dr Agarwal's Eye do?

Dr Agarwals Eye Hospital Ltd is a small-cap chain of eye hospitals in India, founded in 1957, with recent net sales of ₹143 Cr and net profit of ₹23 Cr as of June 2026. The company has a market cap of ₹2,560 Cr and key financial metrics include a P/E ratio of 34.00 and a return on equity of 22.01%.

Overview: <BR>Dr Agarwals Eye Hospital Ltd is a leading chain of eye hospitals in the hospital industry, categorized as a small-cap company.<BR><BR>History: <BR>Founded in 1957, Dr Agarwals Eye Hospital Ltd was incorporated on April 22, 1994. The latest quarterly results reported net sales and net profit for June 2026.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 143 Cr (Quarterly Results - Jun 2026) <BR>Most recent Net Profit: 23 Cr (Quarterly Results - Jun 2026) <BR>Market-cap value: INR 2,560 Cr (Small Cap)<BR><BR>Key Metrics: <BR>P/E: 34.00 <BR>Industry P/E: 67 <BR>Dividend Yield: 0.12% <BR>Debt-Equity: 0.67 <BR>Return on Equity: 22.01% <BR>Price to Book: 7.29<BR><BR>Contact Details: <BR>Address: 3rd Floor Buhari Tower No 4, Moores Road Off Greams Road Chennai Tamil Nadu : 600006 <BR>Tel: 91-44-39916600 <BR>Email: investor@dragarwal.com <BR>Website: http://www.dragarwal.com

Who are the peers of the Dr Agarwal's Eye?

Dr Agarwal's Eye's peers include Yatharth Hospital, Kovai Medical, Jeena Sikho, Artemis Medicare, Indraprastha Medical, KMC Specialty, Shalby, GPT Healthcare, and Unihealth Hospital. In terms of management risk, growth, and capital structure, Dr Agarwal's Eye shows average performance, with a 1-year return of 19.41%.

Peers: The peers of Dr Agarwal's Eye are Yatharth Hospit., Kovai Medical, Jeena Sikho, Artemis Medicare, Indrapr.Medical, KMC Speciality, Shalby, GPT Healthcare, and Unihealth Hosp.<BR><BR>Quality Snapshot: Excellent management risk is observed at Kovai Medical and GPT Healthcare, while Good management risk is found at Yatharth Hospit. and the rest. Average management risk is present at Jeena Sikho, Artemis Medicare, Indrapr.Medical, Dr Agarwal's Eye, KMC Speciality, and Unihealth Hosp, while Below Average management risk is noted at Shalby. In terms of Growth, Excellent growth is seen at Jeena Sikho and Unihealth Hosp, while Good growth is observed at Artemis Medicare, Indrapr.Medical, and Dr Agarwal's Eye, and Average growth is found at Yatharth Hospit., Kovai Medical, KMC Speciality, and the rest. Finally, Excellent capital structure is noted at Jeena Sikho, Indrapr.Medical, and KMC Speciality, while Average capital structure is present at Dr Agarwal's Eye, and Good capital structure is found at Kovai Medical, Artemis Medicare, and Shalby.<BR><BR>Return Snapshot: KMC Speciality has the highest 1-year return at 97.77%, while Jeena Sikho has the lowest at -27.85%. Dr Agarwal's Eye's 1-year return is 19.41%, which is significantly higher than Jeena Sikho's but lower than KMC Speciality's. Additionally, Indrapr.Medical, Jeena Sikho, Shalby, and GPT Healthcare have negative six-month returns.

How big is Dr Agarwal's Eye?

As of 31st August, Dr Agarwals Eye Hospital Ltd has a market capitalization of 2,560.00 Cr, with recent net sales of 496.92 Cr and a net profit of 76.22 Cr.

As of 31st August, Dr Agarwals Eye Hospital Ltd has a market capitalization of 2,560.00 Cr, classifying it as a Small Cap company.<BR><BR>In the latest four quarters, the company reported Net Sales of 496.92 Cr and a Net Profit of 76.22 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with Shareholder's Funds amounting to 209.61 Cr and Total Assets of 603.58 Cr.

Should I buy, sell or hold Dr Agarwals Eye Hospital Ltd?

Are Dr Agarwals Eye Hospital Ltd latest results good or bad?

Dr Agarwal's Eye Hospital Ltd reported strong Q1 FY27 results with a net profit of ₹23.38 crore, up 35.49% year-on-year, and revenue growth of 22.28%. However, operating margins have contracted, raising concerns about profitability amidst rising costs, suggesting cautious investor sentiment.

Dr Agarwal's Eye Hospital Ltd has reported strong financial results for Q1 FY27, showcasing a positive trajectory in both revenue and net profit. The company achieved a net profit of ₹23.38 crore, which reflects a significant year-on-year growth of 35.49% and a quarter-on-quarter increase of 43.97%. Additionally, revenue grew by 22.28% year-on-year, reaching ₹142.97 crore, marking the eighth consecutive quarter of revenue growth.<BR><BR>However, there are concerns regarding the operating margin, which has contracted by 148 basis points year-on-year to 30.26%. This indicates some pressure on profitability despite the strong revenue growth. The increase in employee costs, which rose by nearly 24% year-on-year, has contributed to this margin compression.<BR><BR>The company's return on equity remains robust at 27.84%, indicating effective capital utilization. While the overall financial performance shows strong growth, the margin pressures and rising leverage due to aggressive expansion strategies suggest that investors should approach with caution.<BR><BR>In summary, while the results indicate good revenue and profit growth, the concerns regarding margins and rising costs highlight the need for careful consideration moving forward.

When is the next results date for Dr Agarwals Eye Hospital Ltd?

The next results date for Dr Agarwals Eye Hospital Ltd is 03 August 2026.

The next results date for Dr Agarwals Eye Hospital Ltd is scheduled for 03 August 2026.

Is Dr Agarwal's Eye overvalued or undervalued?

As of November 27, 2025, Dr Agarwal's Eye is considered overvalued with a valuation grade of expensive, reflected in its high PE ratio of 41.45 and a PEG ratio of 1.95, despite strong long-term returns.

As of 27 November 2025, the valuation grade for Dr Agarwal's Eye has moved from fair to expensive, indicating that the company is currently overvalued. The key ratios reflect this assessment, with a PE Ratio of 41.45, an EV to EBITDA of 21.22, and a Price to Book Value of 8.30. These figures suggest that the stock is trading at a premium compared to its earnings and book value.<BR><BR>In comparison to its peers, Dr Agarwal's Eye has a PE ratio that is significantly lower than Max Healthcare's 79.91 but higher than Apollo Hospitals' 63.01, highlighting a mixed competitive landscape. The PEG ratio of 1.95 also suggests that the growth expectations are not justifying the current price level. While the company has shown strong returns over the long term, with a 3-year return of 311.73% compared to the Sensex's 37.61%, the current valuation does not support further upside, leading to the conclusion that Dr Agarwal's Eye is overvalued.

Is Dr Agarwal's Eye technically bullish or bearish?

As of November 25, 2025, the trend is bullish due to positive weekly indicators like the MACD and moving average, though caution is advised from mixed longer-term signals.

As of 25 November 2025, the technical trend has changed from mildly bullish to bullish. The current stance is bullish, driven by a bullish MACD on the weekly timeframe and a bullish daily moving average. The weekly KST also supports this bullish outlook. However, the monthly MACD and KST are mildly bearish, indicating some caution. The RSI on the monthly is bullish, while the Bollinger Bands show a mildly bullish trend on both weekly and monthly charts. Overall, the strength of the bullish stance is moderate, with some mixed signals from the longer-term indicators.

How has been the historical performance of Dr Agarwal's Eye?

Dr Agarwal's Eye has shown significant growth from March 2022 to March 2025, with net sales increasing from 201.21 Cr to 397.15 Cr and profit after tax rising from 24.10 Cr to 54.65 Cr, alongside a substantial rise in total assets and liabilities. The company demonstrates a strong upward trend in profitability and operational cash flow, despite an increase in debt.

Answer:<BR>The historical performance of Dr Agarwal's Eye shows a significant upward trend in net sales and profitability over the years leading up to March 2025.<BR><BR>Breakdown:<BR>Dr Agarwal's Eye has demonstrated strong growth in net sales, increasing from 201.21 Cr in March 2022 to 397.15 Cr in March 2025. This growth is reflected in the total operating income, which also rose from 201.21 Cr to 397.15 Cr during the same period. The company's operating profit (PBDIT) has similarly improved, reaching 123.59 Cr in March 2025, up from 58.94 Cr in March 2022. Profit before tax has followed suit, climbing from 32.31 Cr in March 2022 to 70.70 Cr in March 2025, while profit after tax increased from 24.10 Cr to 54.65 Cr in the same timeframe. The company's total assets grew from 304.27 Cr in March 2022 to 603.58 Cr by March 2025, indicating a solid expansion in its financial base. However, total liabilities also increased from 304.27 Cr to 603.58 Cr, reflecting the company's growing debt, which rose from 31.94 Cr to 96.36 Cr. Cash flow from operating activities improved from 56.00 Cr in March 2022 to 94.00 Cr in March 2025, although the net cash flow showed an outflow of 21.00 Cr in March 2025, down from an inflow of 5.00 Cr in March 2024. Overall, Dr Agarwal's Eye has shown robust growth in sales and profitability, alongside an increase in assets and liabilities, indicating a dynamic expansion strategy.

Who are the top shareholders of the Dr Agarwal's Eye?

The top shareholders of Dr Agarwal's Eye include Dr. Agarwal's Health Care Limited with 71.9%, individual investors with 19.25%, Malabar Midcap Fund at 1.7%, and two foreign institutional investors holding a combined 1.33%. Mutual funds hold a minimal 0.09%.

The top shareholders of Dr Agarwal's Eye include the promoters, with Dr. Agarwal's Health Care Limited holding the largest stake at 71.9%. Additionally, individual investors collectively own 19.25% of the company. Other notable shareholders include Malabar Midcap Fund, which holds 1.7%, and two foreign institutional investors (FIIs) with a combined holding of 1.33%. Mutual funds have a minimal presence, with only 0.09% held by one scheme.

Has Dr Agarwal's Eye declared dividend?

Yes, Dr Agarwal's Eye Hospital Ltd has declared a 25% dividend, amounting to ₹2.5 per share, with an ex-date of November 8, 2024. Despite recent fluctuations, the company has shown strong long-term growth, particularly with a total return of 1751.87% over the past five years.

Dr Agarwals Eye Hospital Ltd has declared a 25% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 25%<BR>- Amount per share: 2.5<BR>- Ex-date: 08 Nov 24<BR><BR>Dividend Yield: 0.11%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -23.34%, with a dividend return of 0%, resulting in a total return of -23.34%.<BR><BR>Over the past year, the price return was 39.51%, the dividend return was 0.15%, leading to a total return of 39.66%.<BR><BR>In the 2-year period, the price return reached 188.71%, with a dividend return of 0.74%, culminating in a total return of 189.45%.<BR><BR>For the 3-year period, the price return was 541.02%, the dividend return was 2.18%, resulting in a total return of 543.2%.<BR><BR>In the last 4 years, the price return was 946.72%, with a dividend return of 3.16%, yielding a total return of 949.88%.<BR><BR>Over the 5-year period, the price return was 1746.12%, the dividend return was 5.75%, leading to a total return of 1751.87%.<BR><BR>Overall, Dr Agarwals Eye Hospital Ltd has declared a dividend, and while the recent returns have shown significant fluctuations, the long-term total returns indicate strong growth, particularly over the 5-year period.